Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhuli Wu

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Drugs in R&D|November 7, 2023
Effect of High-Fat Food on the Pharmacokinetic Profile and Safety of SAF-189s, an ALK/ROS1 Inhibitor, in Healthy Chinese AdultsHuiling Qin, Yan Tan, Lei Diao, et al.
European Journal of Cancer (Oxford, England : 1990)|September 16, 2022
A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanomaLili Mao, Jun Guo, Lingjun Zhu, et al.
Antibody Therapeutics|March 10, 2026
IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapyDianze Chen, Zhuli Wu, Xiwen Zhao, et al.
Lung Cancer (Amsterdam, Netherlands)|March 6, 2022
A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitorsLin Lin, Hongming Pan, Xingya Li, et al.
BMC Medicine|July 3, 2023
Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromasXiaojie Hu, Wenbin Li, Kang Zeng, et al.
Asian Journal of Urology|December 22, 2017
A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and RussiaDingwei Ye, Yiran Huang, Fangjian Zhou, et al.
Targeted Oncology|October 26, 2025
Phase 1 Study of Luvometinib Use in Pediatric Patients with Neurofibromatosis Type 1-Related Unresectable Plexiform NeurofibromasXiaojie Hu, Zhuli Wu, Jinhu Wang, et al.
Nature Communications|June 17, 2024
HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trialQiao Li, Ying Cheng, Zhongsheng Tong, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Drugs in R&D|November 7, 2023
Effect of High-Fat Food on the Pharmacokinetic Profile and Safety of SAF-189s, an ALK/ROS1 Inhibitor, in Healthy Chinese AdultsHuiling Qin, Yan Tan, Lei Diao, et al.
European Journal of Cancer (Oxford, England : 1990)|September 16, 2022
A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanomaLili Mao, Jun Guo, Lingjun Zhu, et al.
Antibody Therapeutics|March 10, 2026
IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapyDianze Chen, Zhuli Wu, Xiwen Zhao, et al.
Lung Cancer (Amsterdam, Netherlands)|March 6, 2022
A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitorsLin Lin, Hongming Pan, Xingya Li, et al.
BMC Medicine|July 3, 2023
Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromasXiaojie Hu, Wenbin Li, Kang Zeng, et al.
Asian Journal of Urology|December 22, 2017
A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and RussiaDingwei Ye, Yiran Huang, Fangjian Zhou, et al.
Targeted Oncology|October 26, 2025
Phase 1 Study of Luvometinib Use in Pediatric Patients with Neurofibromatosis Type 1-Related Unresectable Plexiform NeurofibromasXiaojie Hu, Zhuli Wu, Jinhu Wang, et al.
Nature Communications|June 17, 2024
HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trialQiao Li, Ying Cheng, Zhongsheng Tong, et al.
Pageof 2